Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS

BACKGROUND: Delayed-release dimethyl fumarate (DMF) has demonstrated robust efficacy in treating patients with relapsing-remitting multiple sclerosis. Decreases in absolute lymphocyte count (ALC) are a well-known pharmacodynamic effect of DMF treatment, but lymphocyte recovery dynamics are not well...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Andrew, Rose, John, Alvarez, Enrique, Bar-Or, Amit, Butzkueven, Helmut, Fox, Robert J., Gold, Ralf, Gudesblatt, Mark, Haartsen, Jodi, Spelman, Tim, Wright, Katy, Ferraro, Diana, Sola, Patrizia, Hodgkinson, Suzanne, Kalincik, Tomas, Lechner-Scott, Jeannette, McGuigan, Christopher, Spach, Karen, Chen, Chongshu, Fam, Sami, Wu, Fan, Miller, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837440/
https://www.ncbi.nlm.nih.gov/pubmed/33510947
http://dx.doi.org/10.1212/CPJ.0000000000000800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837440/
https://www.ncbi.nlm.nih.gov/pubmed/33510947
http://dx.doi.org/10.1212/CPJ.0000000000000800

Ejemplares similares